In this podcast episode, we review the major FDA approvals in
psychopharmacology for 2019. We explore brexanolone, bremelanotide,
the asenapine skin patch, esketamine, cariprazine, and
lumateperone.
In this podcast episode, we discuss a case of a 65-year-old
patient with first-episode MDD that is treatment resistant. With
the expertise of Dr. Ken Gillman, we unpack how to manage this case
with an MAOI.
Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from lectures. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.